• linkedin
  • Increase Font
  • Sharebar

    Ultra-widefield angiography: New window for retinovascular features

     

    The PERMEATE study

    In this prospective, open-label trial, the investigators used ultra-widefield angiography and a novel quantification tool developed at the Cleveland Clinic to assess the longitudinal retinal vascular dynamics in patients with DME and RVO.

    The key inclusion criteria were foveal-involving retinal edema secondary to DME or RVO and a best-corrected visual acuity (BCVA) of 20/25 or worse in the study eye. Patients were excluded who had been treated previously with intravitreal pharmacotherapy or laser photocoagulation in the study eye.

    All eyes received intravitreal aflibercept monthly for the first 6 visits and then every other month for the next 6 visits. The patients were evaluated quarterly with ultra-widefield angiography to determine changes in ischemia, leakage, and microaneurysms.

    Dr. Ehlers presented the interim data that included 26 patients who were divided evenly between the 2 retinal pathologies and who completed the 6-month evaluation. At baseline, the mean visual acuity was 20/80 and the mean central subfield thickness (CST) was 500 µm.

    “As expected, the visual acuity outcomes were excellent, with a mean gain of about 17 letters of vision,” Dr. Ehlers reported. “About 38% of eyes achieved a 3-line or greater gain in vision.”

     

    0 Comments

    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available

    Latest Tweets Follow

    var script= ' ';